Product Center
World Influenza Conference 2024 | Decoding New Possibilities for the Future of Influenza Vaccines
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-07-09
- Views:
(Summary description)From July 5 to 7, the 2024 World Influenza Conference, co-sponsored by the Chinese Preventive Medicine Association, the Asia-Pacific Influenza Control Alliance, the Chinese Center for Disease Control and Prevention, and the Chinese Academy of Medical Sciences, was held in Hainan, China.
World Influenza Conference 2024 | Decoding New Possibilities for the Future of Influenza Vaccines
(Summary description)From July 5 to 7, the 2024 World Influenza Conference, co-sponsored by the Chinese Preventive Medicine Association, the Asia-Pacific Influenza Control Alliance, the Chinese Center for Disease Control and Prevention, and the Chinese Academy of Medical Sciences, was held in Hainan, China.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-07-09 14:04
- Views:
From July 5 to 7, the 2024 World Influenza Conference, co-sponsored by the Chinese Preventive Medicine Association, the Asia-Pacific Influenza Control Alliance, the Chinese Center for Disease Control and Prevention, and the Chinese Academy of Medical Sciences, was held in Hainan, China.
Nearly 100 influenza prevention and control experts and public health professionals from five continents gathered in Boao, Hainan, to exchange and share the world's most advanced influenza prevention and control experience under the theme of "Comprehensive Prevention and Control from Influenza to Respiratory Infectious Diseases", and called for joint efforts in global influenza prevention and control.
As one of the supporting organizations of this conference, Ab&B Bio attended the conference with its product, the first domestically developed quadrivalent influenza virus subunit vaccine "Huier Kangxin", and invited a number of industry experts to discuss the recent influenza epidemiological situation and the research progress of new influenza vaccines, providing "subunit" solutions for China's influenza prevention and control.
"Huier Kangxin" has the unique qualities of "three advantages: high purity (of effective antigens), low adverse reactions, and high efficacy", and incorporates special technologies focused on health and safety, providing more possibilities for low-pain and safe vaccination.
After 9 years of dedicated research in subunit vaccines, based on long-term technological accumulation and continuous innovation, Zhonghui Bio (note: original text switches from "Ab&B Bio" to "Zhonghui Bio" here) is committed to creating healthy vaccine solutions that meet market needs, making safety and health a reality.
At the academic seminar held on the afternoon of July 5, experts from the fields of influenza disease monitoring, prevention and control, and clinical trials introduced the recent influenza epidemiological trends, the clinical research progress and application of the newly developed domestic quadrivalent subunit influenza vaccine, and demonstrated the process characteristics, immunogenicity and safety advantages of subunit influenza vaccines to the experts and scholars attending the conference. The quadrivalent subunit influenza vaccine Huier Kangxin will provide a new generation of influenza vaccine options for the 2024-2025 influenza season, supporting China's influenza prevention and control efforts.
At the academic seminar held on the afternoon of July 5, experts from the fields of influenza disease monitoring, prevention and control, and clinical trials introduced the recent influenza epidemiological trends, the clinical research progress and application of the newly developed domestic quadrivalent subunit influenza vaccine, and demonstrated the process characteristics, immunogenicity and safety advantages of subunit influenza vaccines to the experts and scholars attending the conference. The quadrivalent subunit influenza vaccine Huier Kangxin will provide a new generation of influenza vaccine options for the 2024-2025 influenza season, supporting China's influenza prevention and control efforts.
At the sessions held from July 6 to 7, experts mentioned that the current global influenza prevention and control work still faces many challenges: global climate change, urbanization, intensive animal husbandry, and cross-border trade facilitation have amplified the driving factors of influenza epidemics; the mutation and recombination of influenza viruses persist worldwide, and human infection with zoonotic influenza outbreaks also occur from time to time, keeping the risk of influenza pandemics ever-present. Ab&B Bio focuses on the unmet needs in influenza prevention and control, and has developed multiple subunit influenza vaccine products for adults, children, and the elderly. At the same time, Ab&B Bio actively pursues overseas registrations and will contribute more Chinese expertise to global influenza prevention and control.
Biotechnology is reshaping the future of vaccines in an unprecedented way. As an innovation-driven company, Zhonghui Bio has been deeply engaged in subunit vaccines for many years, continuously investing in research and development, accelerating product progress and the development of key technologies, and exploring new paradigms for vaccine innovation and development.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
